A functional human IgM response to HIV-1 Env after immunization with NYVAC HIV C

AIDS

Volumn 21, Issue 4, 2007, Pages 524-527

  Sheppard, Neil C ^a   Bates, Anna C ^a   Sattentau, Quentin J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS VIRUS C ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VECTOR;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IMMUNE RESPONSE; IMMUNIZATION; PRIORITY JOURNAL; TITRIMETRY; VIRUS ENVELOPE;

AIDS VACCINES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRAL VACCINES;

EID: 33847047865     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32803277f9     Document Type: Article

References (14)

1. International AIDS Vaccine Initiative. Special issue: 2005 year in review. In: IAVI Report. New York: International AIDS Vaccine Initiative; 2005.
2. Aasa-Chapman MM, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, et al. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 2005; 79:2823-2830.
3. Nag P, Kim J, Sapiega V, Landay AL, Bremer JW, Mestecky J, et al. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis 2004; 190:1970-1978.
4. Burton D. The anti-HIV activity of antibodies in vitro and in vivo. [Abstract] In: 5th Annual International Conference on AIDS Vaccines. Amsterdam, the Netherlands, 31 August-1 September 2006:S05-02.
5. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin AM, Moog C. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006; 80:6177-6181.
6. Su L, Graf M, Zhang Y, von Briesen H, Xing H, Köstler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B′) recombinant strain in China. J Virol 2000; 74:11367-11376.
7. Pantaleo G. EuroVacc DNAR NYVAC trial update. [Abstract] In: 5th Annual International Conference on AIDS Vaccines. Amsterdam, the Netherlands, 31 August-1 September 2006:S07-04.
8. Bart PA, Harari A, Khonkarly M, Tapia G, Medjitna-Rais E, Burnet S, et al., and EuroVacc. Analysis of the safety and immunogencity of a pox-vector based vaccine expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype C. [Abstract] In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA, 22-25 February 2005:S07.
9. Muzyka A. GraphPad Prism for Windows, version 4.01, Graph-Pad Software, San Diego, California, USA, www.graphpad.com
10. Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 2004; 20:755-762.
11. Wolbank S, Kunert R, Stiegler G, Katinger H. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol 2003; 77:4095-4103.
12. Huerta L, Gomez-Icazbalceta G, Soto-Ramirez L, Viveros-Rogel M, Rodriguez R, Fuentes L, et al. Human immunodeficiency virus 1 (HIV-1) envelope-dependent cell-cell fusion modulation by HIV-positive sera is related to disease progression. J Gen Virol 2005; 86:1961-1966.
13. Ostrowski MA, Chun T, Stanely SK, Fauci AS. Current protocols in immunology. Hoboken: Wiley Interscience; 2001.
14. Sullivan BL, Knopoff EJ, Saifuddin M, Takefman DM, Saarloos MN, Sha BE, Spear GT. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol 1996; 157:1791-1798.